Bellerophon Therapeutics (NASDAQ:BLPH) Now Covered by StockNews.com

Research analysts at StockNews.com started coverage on shares of Bellerophon Therapeutics (NASDAQ:BLPH) in a research note issued to investors on Tuesday. The brokerage set a “hold” rating on the biotechnology company’s stock.

Bellerophon Therapeutics Stock Performance

Shares of BLPH stock opened at $0.06 on Tuesday. The stock has a market cap of $684,880.00, a PE ratio of -0.07 and a beta of 0.71. The company’s fifty day moving average price is $0.06 and its 200-day moving average price is $0.05. Bellerophon Therapeutics has a 12 month low of $0.03 and a 12 month high of $0.76.

Bellerophon Therapeutics Company Profile

Bellerophon Therapeutics, Inc, a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its primary product is INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension.